Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IV safety study of Menjugate meningococcal C vaccine in children
2004-005150-31Phase 4Completed
- Sponsor
- Chiron Behring Vaccines
- Start
- Mar 2005
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of Meningococcal group C polysaccharide conjugate vaccine in Serogroup C meningococcal disease (MenC), sponsored by Chiron Behring Vaccines. Primary endpoints: Memory antibody response to Neisseria meningitidis serogroup C and Serogroup C antibody titers in naive children. Started Mar 2005; status: completed.
02
Drugs
Meningococcal group C polysaccharide conjugate vaccine
03
Conditions
Serogroup C meningococcal disease (MenC)
Beyond the preview
Go deeper on 2004-005150-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-005150-31.